Skip to main content
VCbacked
Log inGet Started

Braveheart Bio

San Francisco, United States

Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.

$185.0M raised
Nov 2025
Series A
BiotechnologyLife ScienceTherapeutics

Top Investors

Andreessen HorowitzOrbiMedForbion Capital PartnersEnavate SciencesFrazier Life Sciences

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Braveheart Bio

How much funding has Braveheart Bio raised?
Braveheart Bio has raised $185.0M in total funding. The most recent round was Series A. The last funding was announced in November 2025.
Who are Braveheart Bio's investors?
Braveheart Bio's investors include Andreessen Horowitz, OrbiMed, Forbion Capital Partners, Enavate Sciences, Frazier Life Sciences.
Where is Braveheart Bio headquartered?
Braveheart Bio is headquartered in San Francisco, United States.
What does Braveheart Bio do?
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
What stage is Braveheart Bio at?
Braveheart Bio is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Braveheart Bio — Funding & Investors." VCBacked, November 5, 2025, https://www.vcbacked.co/company/braveheart-bio. Accessed June 10, 2026.
APA
VCBacked. (2025). Braveheart Bio — Funding & Investors. Retrieved June 10, 2026, from https://www.vcbacked.co/company/braveheart-bio
Wikipedia (cite web)
{{cite web |title=Braveheart Bio — Funding & Investors |url=https://www.vcbacked.co/company/braveheart-bio |website=VCBacked |access-date=June 10, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong